Literature DB >> 25393849

Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model.

Pari V Pandharipande1, Curtis Heberle, Emily C Dowling, Chung Yin Kong, Angela Tramontano, Katherine E Perzan, William Brugge, Chin Hur.   

Abstract

PURPOSE: To identify when, from the standpoint of relative risk, magnetic resonance (MR) imaging-based screening may be effective in patients with a known or suspected genetic predisposition to pancreatic cancer.
MATERIALS AND METHODS: The authors developed a Markov model of pancreatic ductal adenocarcinoma (PDAC). The model was calibrated to National Cancer Institute Surveillance, Epidemiology, and End Results registry data and informed by the literature. A hypothetical screening strategy was evaluated in which all population individuals underwent one-time MR imaging screening at age 50 years. Screening outcomes for individuals with an average risk for PDAC ("base case") were compared with those for individuals at an increased risk to assess for differential benefits in populations with a known or suspected genetic predisposition. Effects of varying key inputs, including MR imaging performance, surgical mortality, and screening age, were evaluated with a sensitivity analysis. RESULTS In the base case, screening resulted in a small number of cancer deaths averted (39 of 100 000 men, 38 of 100 000 women) and a net decrease in life expectancy (-3 days for men, -4 days for women), which was driven by unnecessary pancreatic surgeries associated with false-positive results. Life expectancy gains were achieved if an individual's risk for PDAC exceeded 2.4 (men) or 2.7 (women) times that of the general population. When relative risk increased further, for example to 30 times that of the general population, averted cancer deaths and life expectancy gains increased substantially (1219 of 100 000 men, life expectancy gain: 65 days; 1204 of 100 000 women, life expectancy gain: 71 days). In addition, results were sensitive to MR imaging specificity and the surgical mortality rate.
CONCLUSION: Although PDAC screening with MR imaging for the entire population is not effective, individuals with even modestly increased risk may benefit. © RSNA, 2014 Online supplemental material is available for this article.

Entities:  

Mesh:

Year:  2014        PMID: 25393849      PMCID: PMC4372492          DOI: 10.1148/radiol.14141282

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  57 in total

1.  Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia.

Authors:  Chin Hur; Norman S Nishioka; G Scott Gazelle
Journal:  Dig Dis Sci       Date:  2003-07       Impact factor: 3.199

Review 2.  The role of endoscopy in the evaluation and treatment of patients with pancreaticobiliary malignancy.

Authors:  Todd H Baron; J Shawn Mallery; William K Hirota; Jay L Goldstein; Brian C Jacobson; Jonathan A Leighton; J Patrick Waring; Douglas O Faigel
Journal:  Gastrointest Endosc       Date:  2003-11       Impact factor: 9.427

3.  Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series.

Authors:  Klaus Sahora; Mari Mino-Kenudson; William Brugge; Sarah P Thayer; Cristina R Ferrone; Dushyant Sahani; Martha B Pitman; Andrew L Warshaw; Keith D Lillemoe; Carlos F Fernandez-del Castillo
Journal:  Ann Surg       Date:  2013-09       Impact factor: 12.969

4.  Screening and surveillance for hereditary pancreatic cancer.

Authors:  Michael B Kimmey; Mary P Bronner; David R Byrd; Teresa A Brentnall
Journal:  Gastrointest Endosc       Date:  2002-10       Impact factor: 9.427

5.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

Authors:  Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian
Journal:  Cancer Res       Date:  2014-06-01       Impact factor: 12.701

6.  Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients.

Authors:  Carlos Fernández-del Castillo; Javier Targarona; Sarah P Thayer; David W Rattner; William R Brugge; Andrew L Warshaw
Journal:  Arch Surg       Date:  2003-04

7.  Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds.

Authors:  Stephen J Rulyak; Michael B Kimmey; David L Veenstra; Teresa A Brentnall
Journal:  Gastrointest Endosc       Date:  2003-01       Impact factor: 9.427

8.  An analysis of the reduced morbidity and mortality rates after pancreaticoduodenectomy.

Authors:  C A Pellegrini; C F Heck; S Raper; L W Way
Journal:  Arch Surg       Date:  1989-07

Review 9.  Breast cancer screening in an era of personalized regimens: a conceptual model and National Cancer Institute initiative for risk-based and preference-based approaches at a population level.

Authors:  Tracy Onega; Elisabeth F Beaber; Brian L Sprague; William E Barlow; Jennifer S Haas; Anna N A Tosteson; Mitchell D Schnall; Katrina Armstrong; Marilyn M Schapira; Berta Geller; Donald L Weaver; Emily F Conant
Journal:  Cancer       Date:  2014-05-15       Impact factor: 6.860

10.  Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force.

Authors:  Harry J de Koning; Rafael Meza; Sylvia K Plevritis; Kevin ten Haaf; Vidit N Munshi; Jihyoun Jeon; Saadet Ayca Erdogan; Chung Yin Kong; Summer S Han; Joost van Rosmalen; Sung Eun Choi; Paul F Pinsky; Amy Berrington de Gonzalez; Christine D Berg; William C Black; Martin C Tammemägi; William D Hazelton; Eric J Feuer; Pamela M McMahon
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

View more
  9 in total

1.  Early Pancreatic Ductal Adenocarcinoma Survival Is Dependent on Size: Positive Implications for Future Targeted Screening.

Authors:  Chin Hur; Angela C Tramontano; Emily C Dowling; Gabriel A Brooks; Alvin Jeon; William R Brugge; G Scott Gazelle; Chung Yin Kong; Pari V Pandharipande
Journal:  Pancreas       Date:  2016-08       Impact factor: 3.327

2.  Self-Reported Questionnaire Detects Family History of Cancer in a Pancreatic Cancer Screening Program.

Authors:  Aimee L Lucas; Adam Tarlecki; Kellie Van Beck; Casey Lipton; Arindam RoyChoudhury; Elana Levinson; Sheila Kumar; Wendy K Chung; Harold Frucht; Jeanine M Genkinger
Journal:  J Genet Couns       Date:  2016-12-30       Impact factor: 2.537

3.  Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model.

Authors:  Mary Linton B Peters; Andrew Eckel; Anna Lietz; Claudia Seguin; Peter Mueller; Chin Hur; Pari V Pandharipande
Journal:  Pancreatology       Date:  2022-05-31       Impact factor: 3.977

4.  Combining in Vitro Diagnostics with in Vivo Imaging for Earlier Detection of Pancreatic Ductal Adenocarcinoma: Challenges and Solutions.

Authors:  Paul F Laeseke; Ru Chen; R Brooke Jeffrey; Teresa A Brentnall; Jürgen K Willmann
Journal:  Radiology       Date:  2015-12       Impact factor: 11.105

5.  CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation.

Authors:  Kazufumi Honda; Verena A Katzke; Anika Hüsing; Shinobu Okaya; Hirokazu Shoji; Kaoru Onidani; Anja Olsen; Anne Tjønneland; Kim Overvad; Elisabete Weiderpass; Paolo Vineis; David Muller; Kostas Tsilidis; Domenico Palli; Valeria Pala; Rosario Tumino; Alessio Naccarati; Salvatore Panico; Krasimira Aleksandrova; Heiner Boeing; H Bas Bueno-de-Mesquita; Petra H Peeters; Antonia Trichopoulou; Pagona Lagiou; Kay-Tee Khaw; Nick Wareham; Ruth C Travis; Susana Merino; Eric J Duell; Miguel Rodríguez-Barranco; María Dolores Chirlaque; Aurelio Barricarte; Vinciane Rebours; Marie-Chiristine Boutron-Ruault; Francesca Romana Mancini; Paul Brennan; Ghislaine Scelo; Jonas Manjer; Malin Sund; Daniel Öhlund; Federico Canzian; Rudolf Kaaks
Journal:  Int J Cancer       Date:  2018-12-04       Impact factor: 7.396

Review 6.  Universal cancer screening: revolutionary, rational, and realizable.

Authors:  David A Ahlquist
Journal:  NPJ Precis Oncol       Date:  2018-10-29

7.  Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model.

Authors:  Mary Linton B Peters; Andrew Eckel; Peter P Mueller; Angela C Tramontano; Davis T Weaver; Anna Lietz; Chin Hur; Chung Yin Kong; Pari V Pandharipande
Journal:  Pancreatology       Date:  2018-07-29       Impact factor: 3.977

8.  Screening for Pancreatic Adenocarcinoma in BRCA2 Mutation Carriers: Results of a Disease Simulation Model.

Authors:  Pari V Pandharipande; Alvin Jeon; Curtis R Heberle; Emily C Dowling; Chung Yin Kong; Daniel C Chung; William R Brugge; Chin Hur
Journal:  EBioMedicine       Date:  2015-11-04       Impact factor: 8.143

Review 9.  Prevention of pancreatic cancer.

Authors:  Stefan Kuroczycki-Saniutycz; Agnieszka Grzeszczuk; Zbigniew Wojciech Zwierz; Paweł Kołodziejczyk; Jakub Szczesiul; Beata Zalewska-Szajda; Krystyna Ościłowicz; Napoleon Waszkiewicz; Krzysztof Zwierz; Sławomir Dariusz Szajda
Journal:  Contemp Oncol (Pozn)       Date:  2017-03-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.